<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Diabetes Care</journal-id><journal-id journal-id-type="hwp">diacare</journal-id><journal-id journal-id-type="pmc">dcare</journal-id><journal-id journal-id-type="publisher-id">Diabetes Care</journal-id><journal-title-group><journal-title>Diabetes Care</journal-title></journal-title-group><issn pub-type="ppub">0149-5992</issn><issn pub-type="epub">1935-5548</issn><publisher><publisher-name>American Diabetes Association</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">20200301</article-id><article-id pub-id-type="pmc">2875419</article-id><article-id pub-id-type="publisher-id">2294</article-id><article-id pub-id-type="doi">10.2337/dc09-2294</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject><subj-group><subject>Clinical Care/Education/Nutrition/Psychosocial Research</subject></subj-group></subj-group></article-categories><title-group><article-title>A 24-Week, Randomized, Treat-to-Target Trial Comparing Initiation of Insulin Glargine Once-Daily With Insulin Detemir Twice-Daily in Patients With Type 2 Diabetes Inadequately Controlled on Oral Glucose-Lowering Drugs</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Swinnen</surname><given-names>Sanne G.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"></xref></contrib><contrib contrib-type="author"><name><surname>Dain</surname><given-names>Marie-Paule</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Aronson</surname><given-names>Ronnie</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Davies</surname><given-names>Melanie</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Gerstein</surname><given-names>Hertzel C.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff5"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Pfeiffer</surname><given-names>Andreas F.</given-names></name><degrees>MD, PHD</degrees><xref ref-type="aff" rid="aff6"><sup>6</sup></xref></contrib><contrib contrib-type="author"><name><surname>Snoek</surname><given-names>Frank J.</given-names></name><degrees>PHD</degrees><xref ref-type="aff" rid="aff7"><sup>7</sup></xref></contrib><contrib contrib-type="author"><name><surname>DeVries</surname><given-names>J. Hans</given-names></name><degrees>MD, PHD</degrees><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Hoekstra</surname><given-names>Joost B.</given-names></name><degrees>MD, PHD</degrees><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Holleman</surname><given-names>Frits</given-names></name><degrees>MD, PHD</degrees><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><aff id="aff1"><sup>1</sup>Department of Internal Medicine, Academic Medical Center, Amsterdam, the Netherlands; </aff><aff id="aff2"><sup>2</sup>Global Metabolism, sanofi-aventis, Paris, France; </aff><aff id="aff3"><sup>3</sup>LMC Endocrinology Centers, Toronto, Ontario, Canada; </aff><aff id="aff4"><sup>4</sup>Department of Cardiovascular Sciences, University of Leicester, Leicester Royal Infirmary, Leicester, U.K.; </aff><aff id="aff5"><sup>5</sup>Division of Endocrinology and Metabolism, McMaster University Medical Center, Hamilton, Ontario, Canada; </aff><aff id="aff6"><sup>6</sup>Department of Endocrinology, Diabetes and Nutrition, Charité University Medicine, Berlin, Germany; </aff><aff id="aff7"><sup>7</sup>Department of Medical Psychology, VU University Medical Center, Amsterdam, the Netherlands.</aff></contrib-group><author-notes><corresp id="cor1">Corresponding author: Sanne G. Swinnen, <email>s.g.swinnen@amc.uva.nl</email>.</corresp></author-notes><pub-date pub-type="ppub"><month>6</month><year>2010</year></pub-date><pub-date pub-type="epub"><day>3</day><month>3</month><year>2010</year></pub-date><volume>33</volume><issue>6</issue><fpage>1176</fpage><lpage>1178</lpage><history><date date-type="received"><day>16</day><month>12</month><year>2009</year></date><date date-type="accepted"><day>22</day><month>2</month><year>2010</year></date></history><permissions><copyright-statement>© 2010 by the American Diabetes Association.</copyright-statement><license license-type="creative-commons"><license-p>Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/3.0/">http://creativecommons.org/licenses/by-nc-nd/3.0/</ext-link> for details.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:type="simple" xlink:href="zdc00610001176.pdf"></self-uri><abstract><sec><title><offsets xml_i="5325" xml_f="5334" txt_i="11" txt_f="20">OBJECTIVE</offsets></title><p><offsets xml_i="5345" xml_f="5503" txt_i="21" txt_f="176">To determine whether glargine is noninferior to detemir regarding the percentage of patients reaching A1C &lt;7% without symptomatic hypoglycemia ≤3.1 mmol/l.</offsets></p></sec><sec><title><offsets xml_i="5525" xml_f="5552" txt_i="178" txt_f="205">RESEARCH DESIGN AND METHODS</offsets></title><p><offsets xml_i="5563" xml_f="5792" txt_i="206" txt_f="435">In this 24-week trial, 973 insulin-naive type 2 diabetic patients on stable oral glucose-lowering drugs with A1C 7.0–10.5% were randomized to glargine once daily or detemir twice daily. Insulin doses were systematically titrated.</offsets></p></sec><sec><title><offsets xml_i="5814" xml_f="5821" txt_i="437" txt_f="444">RESULTS</offsets></title><p><offsets xml_i="5832" xml_f="6057" txt_i="445" txt_f="670">27.5 and 25.6% of patients reached the primary outcome with glargine and detemir, respectively, demonstrating the noninferiority of glargine. Improvements in A1C were −1.46 ± 1.09% for glargine and −1.54 ± 1.11% for detemir (</offsets><italic><offsets xml_i="6065" xml_f="6066" txt_i="670" txt_f="671">P</offsets></italic><offsets xml_i="6075" xml_f="6145" txt_i="671" txt_f="738"> = 0.149), with similar proportions of patients achieving A1C &lt;7% (</offsets><italic><offsets xml_i="6153" xml_f="6154" txt_i="738" txt_f="739">P</offsets></italic><offsets xml_i="6163" xml_f="6230" txt_i="739" txt_f="803"> = 0.254) but more detemir-treated patients reaching A1C &lt;6.5% (</offsets><italic><offsets xml_i="6238" xml_f="6239" txt_i="803" txt_f="804">P</offsets></italic><offsets xml_i="6248" xml_f="6348" txt_i="804" txt_f="904"> = 0.017). Hypoglycemia risk was similar. Weight gain was higher for glargine (difference: 0.77 kg, </offsets><italic><offsets xml_i="6356" xml_f="6357" txt_i="904" txt_f="905">P</offsets></italic><offsets xml_i="6366" xml_f="6465" txt_i="905" txt_f="1001"> &lt; 0.001). Glargine doses were lower than detemir doses: 43.5 ± 29.0 vs. 76.5 ± 50.5 units/day (</offsets><italic><offsets xml_i="6473" xml_f="6474" txt_i="1001" txt_f="1002">P</offsets></italic><offsets xml_i="6483" xml_f="6496" txt_i="1002" txt_f="1012"> &lt; 0.001).</offsets></p></sec><sec><title><offsets xml_i="6518" xml_f="6529" txt_i="1014" txt_f="1025">CONCLUSIONS</offsets></title><p><offsets xml_i="6540" xml_f="6690" txt_i="1026" txt_f="1176">In insulin-naive type 2 diabetic patients, glargine reached similar control as detemir, with more weight gain, but required significantly lower doses.</offsets></p></sec></abstract></article-meta></front><body><p><offsets xml_i="6743" xml_f="6970" txt_i="1185" txt_f="1412">The “treat-to-target” clinical trials have demonstrated that the addition of systematically titrated basal insulin to existing oral therapy results in adequate glycemic control in the majority of patients with type 2 diabetes (</offsets><xref ref-type="bibr" rid="B1"><offsets xml_i="7001" xml_f="7002" txt_i="1412" txt_f="1413">1</offsets></xref><xref ref-type="bibr" rid="B2"></xref><offsets xml_i="7047" xml_f="7048" txt_i="1413" txt_f="1414">–</offsets><xref ref-type="bibr" rid="B3"><offsets xml_i="7079" xml_f="7080" txt_i="1414" txt_f="1415">3</offsets></xref><offsets xml_i="7087" xml_f="7248" txt_i="1415" txt_f="1576">). The basal insulin analogs, insulin glargine and insulin detemir, achieve this with a reduced risk of hypoglycemia compared with the conventional NPH insulin (</offsets><xref ref-type="bibr" rid="B1"><offsets xml_i="7279" xml_f="7280" txt_i="1576" txt_f="1577">1</offsets></xref><offsets xml_i="7287" xml_f="7288" txt_i="1577" txt_f="1578">,</offsets><xref ref-type="bibr" rid="B2"><offsets xml_i="7319" xml_f="7320" txt_i="1578" txt_f="1579">2</offsets></xref><offsets xml_i="7327" xml_f="7813" txt_i="1579" txt_f="2062">). The aim of this study was to compare the efficacy, safety, and the effect on quality of life of once-daily glargine with twice-daily detemir in insulin-naive patients with type 2 diabetes inadequately controlled on oral glucose-lowering drugs (OGLDs), including metformin. The primary objective was to determine whether glargine was noninferior to detemir regarding the percentage of patients reaching A1C &lt;7% without symptomatic hypoglycemia with plasma glucose (PG) ≤3.1 mmol/l.</offsets></p><sec><title><offsets xml_i="7829" xml_f="7856" txt_i="2063" txt_f="2090">RESEARCH DESIGN AND METHODS</offsets></title><p><offsets xml_i="7867" xml_f="7969" txt_i="2091" txt_f="2193">The rationale for dosing detemir twice daily and the study methods we used have been detailed before (</offsets><xref ref-type="bibr" rid="B4"><offsets xml_i="8000" xml_f="8001" txt_i="2193" txt_f="2194">4</offsets></xref><offsets xml_i="8008" xml_f="8509" txt_i="2194" txt_f="2689">). In brief, this multinational, open-label trial randomized insulin-naive type 2 diabetic subjects treated for ≥3 months with stable OGLDs (including metformin ≥1 g/day) and with A1C of 7.0–10.5%, to 24-week treatment with glargine in the evening or detemir at breakfast and dinner. Glargine doses were increased every 2 days by 2 units until fasting PG reached &lt;5.6 mmol/l, while the systematic titration of detemir involved three steps to obtain both fasting and predinner PG of &lt;5.6 mmol/l (</offsets><xref ref-type="bibr" rid="B4"><offsets xml_i="8540" xml_f="8541" txt_i="2689" txt_f="2690">4</offsets></xref><offsets xml_i="8548" xml_f="8550" txt_i="2690" txt_f="2692">).</offsets></p><p><offsets xml_i="8557" xml_f="8835" txt_i="2693" txt_f="2962">The primary outcome was the percentage of patients reaching A1C &lt;7% without symptomatic hypoglycemia confirmed by PG ≤3.1 mmol/l. Secondary outcomes included proportions of patients achieving A1C &lt;7% and &lt;6.5%, hypoglycemia, weight, insulin doses, and quality of life (</offsets><xref ref-type="bibr" rid="B5"><offsets xml_i="8866" xml_f="8867" txt_i="2962" txt_f="2963">5</offsets></xref><xref ref-type="bibr" rid="B6"></xref><xref ref-type="bibr" rid="B7"></xref><offsets xml_i="8950" xml_f="8951" txt_i="2963" txt_f="2964">–</offsets><xref ref-type="bibr" rid="B8"><offsets xml_i="8982" xml_f="8983" txt_i="2964" txt_f="2965">8</offsets></xref><offsets xml_i="8990" xml_f="8992" txt_i="2965" txt_f="2967">).</offsets></p><p><offsets xml_i="8999" xml_f="9251" txt_i="2968" txt_f="3220">Noninferiority of glargine to detemir was accepted if the lower limit of the two-sided 95% CI for the difference in the proportions of patients reaching the primary outcome was ≥30% of the percentage of detemir-treated patients achieving this outcome (</offsets><xref ref-type="bibr" rid="B4"><offsets xml_i="9282" xml_f="9283" txt_i="3220" txt_f="3221">4</offsets></xref><offsets xml_i="9290" xml_f="9292" txt_i="3221" txt_f="3223">).</offsets></p></sec><sec sec-type="results"><title><offsets xml_i="9333" xml_f="9340" txt_i="3225" txt_f="3232">RESULTS</offsets></title><p><offsets xml_i="9351" xml_f="9550" txt_i="3233" txt_f="3432">Of 1,230 patients screened, 973 were randomized, and 478 were treated with glargine and 486 with detemir. More patients on glargine than on detemir completed the study (95.4 and 89.9%, respectively, </offsets><italic><offsets xml_i="9558" xml_f="9559" txt_i="3432" txt_f="3433">P</offsets></italic><offsets xml_i="9568" xml_f="9795" txt_i="3433" txt_f="3660"> = 0.001). The main reason for study discontinuation was an adverse event: 7 patients on glargine (1 event possibly related to study drug) and 22 on detemir (20 possibly related) dropped out of the study due to adverse events (</offsets><italic><offsets xml_i="9803" xml_f="9804" txt_i="3660" txt_f="3661">P</offsets></italic><offsets xml_i="9813" xml_f="9874" txt_i="3661" txt_f="3722"> = 0.005) (online Fig. A, available in an online appendix at </offsets><ext-link ext-link-type="uri" xlink:href="http://care.diabetesjournals.org/cgi/content/full/dc09-2294"><offsets xml_i="9977" xml_f="10036" txt_i="3722" txt_f="3781">http://care.diabetesjournals.org/cgi/content/full/dc09-2294</offsets></ext-link><offsets xml_i="10047" xml_f="10275" txt_i="3781" txt_f="4009">). Online Table A shows the population's baseline characteristics. Of 865 patients using insulin secretagogs at study entry, 42.4% stopped these at randomization (43.5 and 41.4% in the glargine and detemir groups, respectively).</offsets></p><p><offsets xml_i="10282" xml_f="10561" txt_i="4010" txt_f="4286">In the glargine and detemir groups, 27.5 and 25.6% of patients, respectively, reached A1C &lt;7% without symptomatic hypoglycemia with PG ≤3.1 mmol/l (difference: 1.85% [95% CI −3.78 to 7.48%]), demonstrating noninferiority of glargine to detemir (noninferiority margin: −7.68%).</offsets></p><sec><title><offsets xml_i="10577" xml_f="10595" txt_i="4287" txt_f="4305">Secondary outcomes</offsets></title><p><xref ref-type="fig" rid="F1"><offsets xml_i="10636" xml_f="10642" txt_i="4306" txt_f="4312">Fig. 1</offsets></xref><italic><offsets xml_i="10657" xml_f="10658" txt_i="4312" txt_f="4313">A</offsets></italic><offsets xml_i="10667" xml_f="10786" txt_i="4313" txt_f="4432"> illustrates that the mean improvements in A1C were similar: −1.46 ± 1.09% for glargine and −1.54 ± 1.11% for detemir (</offsets><italic><offsets xml_i="10794" xml_f="10795" txt_i="4432" txt_f="4433">P</offsets></italic><offsets xml_i="10804" xml_f="10913" txt_i="4433" txt_f="4539"> = 0.149). The proportions of patients achieving A1C &lt;7% were also similar (44.1 and 47.8%, respectively, </offsets><italic><offsets xml_i="10921" xml_f="10922" txt_i="4539" txt_f="4540">P</offsets></italic><offsets xml_i="10931" xml_f="11058" txt_i="4540" txt_f="4664"> = 0.254), but significantly fewer glargine- than detemir-treated patients reached A1C &lt;6.5% (16.5 and 22.7%, respectively, </offsets><italic><offsets xml_i="11066" xml_f="11067" txt_i="4664" txt_f="4665">P</offsets></italic><offsets xml_i="11076" xml_f="11223" txt_i="4665" txt_f="4812"> = 0.017). The 8-point PG profiles at baseline and end-of-study show that while the decrease in fasting PG was significantly greater for glargine (</offsets><italic><offsets xml_i="11231" xml_f="11232" txt_i="4812" txt_f="4813">P</offsets></italic><offsets xml_i="11241" xml_f="11382" txt_i="4813" txt_f="4951"> &lt; 0.001), detemir resulted in significantly larger reductions in PG before and after lunch, before and after dinner, and at bedtime (all </offsets><italic><offsets xml_i="11390" xml_f="11391" txt_i="4951" txt_f="4952">P</offsets></italic><offsets xml_i="11400" xml_f="11429" txt_i="4952" txt_f="4978"> &lt; 0.001) (online Fig. B).</offsets></p><fig id="F1" position="float"><label><offsets xml_i="11470" xml_f="11478" txt_i="4979" txt_f="4987">Figure 1</offsets></label><caption><p><offsets xml_i="11498" xml_f="11510" txt_i="4987" txt_f="4999">A1C levels (</offsets><italic><offsets xml_i="11518" xml_f="11519" txt_i="4999" txt_f="5000">A</offsets></italic><offsets xml_i="11528" xml_f="11555" txt_i="5000" txt_f="5027">) and daily insulin doses (</offsets><italic><offsets xml_i="11563" xml_f="11564" txt_i="5027" txt_f="5028">B</offsets></italic><offsets xml_i="11573" xml_f="11611" txt_i="5028" txt_f="5066">) during the 24-week treatment period.</offsets></p></caption><graphic xlink:href="zdc0061082540001"></graphic></fig><p><offsets xml_i="11683" xml_f="11947" txt_i="5067" txt_f="5331">Risk of hypoglycemia was comparable between treatments with ∼30% of patients experiencing symptomatic hypoglycemia with PG ≤3.1 mmol/l in either group (online Table B). Weight gain was significantly higher with glargine versus detemir: 1.4 ± 3.2 and 0.6 ± 2.9 kg (</offsets><italic><offsets xml_i="11955" xml_f="11956" txt_i="5331" txt_f="5332">P</offsets></italic><offsets xml_i="11965" xml_f="12084" txt_i="5332" txt_f="5448"> &lt; 0.001). Insulin doses, however, were significantly lower for glargine: 43.5 ± 29.0 versus 76.5 ± 50.5 units/day (</offsets><italic><offsets xml_i="12092" xml_f="12093" txt_i="5448" txt_f="5449">P</offsets></italic><offsets xml_i="12102" xml_f="12116" txt_i="5449" txt_f="5460"> &lt; 0.001) (</offsets><xref ref-type="fig" rid="F1"><offsets xml_i="12146" xml_f="12152" txt_i="5460" txt_f="5466">Fig. 1</offsets></xref><italic><offsets xml_i="12167" xml_f="12168" txt_i="5466" txt_f="5467">B</offsets></italic><offsets xml_i="12177" xml_f="12347" txt_i="5467" txt_f="5637">). Quality of life improved during the study with no differences between groups, except for a discrepancy in treatment satisfaction in favor of glargine (online Table C).</offsets></p></sec></sec><sec sec-type="conclusions"><title><offsets xml_i="12398" xml_f="12409" txt_i="5640" txt_f="5651">CONCLUSIONS</offsets></title><p><offsets xml_i="12420" xml_f="12884" txt_i="5652" txt_f="6116">This “treat-to-target” comparison between glargine and detemir in insulin-naive patients with type 2 diabetes demonstrated that glargine and detemir result in similar improvements in A1C and similar risk of hypoglycemia. In addition, our study confirms the higher weight gain, lower daily insulin doses, and fewer drop-outs (because of adverse events) for glargine versus detemir, found in the previous comparison of the two basal analogues in this patient group (</offsets><xref ref-type="bibr" rid="B3"><offsets xml_i="12915" xml_f="12916" txt_i="6116" txt_f="6117">3</offsets></xref><offsets xml_i="12923" xml_f="13079" txt_i="6117" txt_f="6273">). Finally, our findings suggest that initiating glargine or detemir in patients not achieving adequate control on OGLDs positively affects quality of life.</offsets></p><p><offsets xml_i="13086" xml_f="13295" txt_i="6274" txt_f="6483">Our study indicates that higher detemir doses may be needed to obtain the same level of glycemic control as with other basal insulins. This difference has been attributed to the twice-daily dosing of detemir (</offsets><xref ref-type="bibr" rid="B9"><offsets xml_i="13326" xml_f="13327" txt_i="6483" txt_f="6484">9</offsets></xref><offsets xml_i="13334" xml_f="13397" txt_i="6484" txt_f="6547">), but NPH dosed twice-daily does not lead to dose escalation (</offsets><xref ref-type="bibr" rid="B1"><offsets xml_i="13428" xml_f="13429" txt_i="6547" txt_f="6548">1</offsets></xref><offsets xml_i="13436" xml_f="13649" txt_i="6548" txt_f="6761">). Moreover, trial data suggest that, although insulin doses are indeed higher in patients using detemir twice- versus once-daily, once-daily detemir doses are still higher than once-daily NPH and glargine doses (</offsets><xref ref-type="bibr" rid="B3"><offsets xml_i="13680" xml_f="13681" txt_i="6761" txt_f="6762">3</offsets></xref><offsets xml_i="13688" xml_f="13689" txt_i="6762" txt_f="6763">,</offsets><xref ref-type="bibr" rid="B10"><offsets xml_i="13721" xml_f="13723" txt_i="6763" txt_f="6765">10</offsets></xref><offsets xml_i="13730" xml_f="13731" txt_i="6765" txt_f="6766">,</offsets><xref ref-type="bibr" rid="B11"><offsets xml_i="13763" xml_f="13765" txt_i="6766" txt_f="6768">11</offsets></xref><offsets xml_i="13772" xml_f="13865" txt_i="6768" txt_f="6861">). At present there is no clear explanation for the increased dose requirements for detemir (</offsets><xref ref-type="bibr" rid="B12"><offsets xml_i="13897" xml_f="13899" txt_i="6861" txt_f="6863">12</offsets></xref><offsets xml_i="13906" xml_f="13908" txt_i="6863" txt_f="6865">).</offsets></p><p><offsets xml_i="13915" xml_f="14109" txt_i="6866" txt_f="7060">A limitation of our study was its open-label design. This design was necessary, however, as detemir was dosed twice-daily with a separate titration target before dinner. As explained elsewhere (</offsets><xref ref-type="bibr" rid="B4"><offsets xml_i="14140" xml_f="14141" txt_i="7060" txt_f="7061">4</offsets></xref><offsets xml_i="14148" xml_f="14354" txt_i="7061" txt_f="7267">), we deliberately chose to dose detemir twice-daily. Trial data available at the time of the current study's design suggested that twice-daily detemir reached superior A1C compared with once-daily dosing (</offsets><xref ref-type="bibr" rid="B1"><offsets xml_i="14385" xml_f="14386" txt_i="7267" txt_f="7268">1</offsets></xref><offsets xml_i="14393" xml_f="14394" txt_i="7268" txt_f="7269">,</offsets><xref ref-type="bibr" rid="B13"><offsets xml_i="14426" xml_f="14428" txt_i="7269" txt_f="7271">13</offsets></xref><offsets xml_i="14435" xml_f="14936" txt_i="7271" txt_f="7772">). The difference in dosing schedule for the two insulins does, however, affect the interpretation of some of our findings. Advantages of glargine over detemir, such as the greater increase in treatment satisfaction, may be explained by its once-daily dosing and less complex titration. Also, since the design of our study, the current recommendation has become to initiate detemir once-daily (based on a more recent once-daily detemir versus NPH trial showing noninferior A1C reductions for detemir (</offsets><xref ref-type="bibr" rid="B11"><offsets xml_i="14968" xml_f="14970" txt_i="7772" txt_f="7774">11</offsets></xref><offsets xml_i="14977" xml_f="15155" txt_i="7774" txt_f="7952">). Thus, with advancing knowledge, it is now clear that another “treat-to-target” trial comparing both basal analogues using an identical, once-daily dosing regimen is desirable.</offsets></p><p><offsets xml_i="15162" xml_f="15545" txt_i="7953" txt_f="8333">In conclusion, we demonstrated that in insulin-naive patients with type 2 diabetes glargine once-daily is noninferior to detemir twice-daily regarding the percentage of patients reaching target A1C without hypoglycemia. Detemir-treated patients had less weight gain and more often achieved A1C &lt;6.5%, but the drop-out rate and daily insulin doses were lower in the glargine group.</offsets></p></sec><offsets xml_i="15555" xml_f="15562" txt_i="8335" txt_f="8342">
      </offsets><sec sec-type="supplementary-material"><offsets xml_i="15601" xml_f="15611" txt_i="8342" txt_f="8352">
         </offsets><title><offsets xml_i="15618" xml_f="15640" txt_i="8352" txt_f="8374">Supplementary Material</offsets></title><offsets xml_i="15648" xml_f="15658" txt_i="8375" txt_f="8385">
         </offsets><supplementary-material id="PMC_1" content-type="local-data"><offsets xml_i="15719" xml_f="15732" txt_i="8385" txt_f="8398">
            </offsets><caption><offsets xml_i="15741" xml_f="15757" txt_i="8398" txt_f="8414">
               </offsets><title><offsets xml_i="15764" xml_f="15779" txt_i="8414" txt_f="8429">Online Appendix</offsets></title><offsets xml_i="15787" xml_f="15800" txt_i="8430" txt_f="8443">
            </offsets></caption><offsets xml_i="15810" xml_f="15823" txt_i="8443" txt_f="8456">
            </offsets><media mimetype="text" mime-subtype="html" xlink:href="supp_33_6_1176__index.html"></media><offsets xml_i="15914" xml_f="15927" txt_i="8456" txt_f="8469">
            </offsets><media xlink:role="associated-file" mimetype="application" mime-subtype="pdf" xlink:href="supp_dc09-2294_onlineappendix.pdf"></media><offsets xml_i="16060" xml_f="16070" txt_i="8469" txt_f="8479">
         </offsets></supplementary-material><offsets xml_i="16095" xml_f="16102" txt_i="8479" txt_f="8486">
      </offsets></sec><offsets xml_i="16108" xml_f="16112" txt_i="8487" txt_f="8491">
   </offsets></body><back><fn-group><fn fn-type="other"><p>Clinical trial reg. no.: NCT00405418, <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov">clinicaltrials.gov</ext-link>.</p></fn><fn fn-type="financial-disclosure"><p>The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.</p></fn></fn-group><ack><title>Acknowledgments</title><p>The study was sponsored by sanofi-aventis, Paris, France. S.G.S. is employed by the Department of Internal Medicine of the Academic Medical Center, partly through funding from Novo Nordisk and sanofi-aventis for the conduct of clinical trials. M-P.D. is employed by sanofi-aventis. R.A., A.F.P., and J.B.H. have acted as a scientific consultants and speakers for sanofi-aventis. M.D., H.C.G., F.J.S., and J.H.D. have received honoraria for consulting and speaking, as well as grants for research from Novo Nordisk and sanofi-aventis. F.H. has acted as a consultant for sanofi-aventis and received a study grant from Novo Nordisk.</p><p>No other potential conflicts of interest relevant to this article were reported.</p><p>Additional acknowledgments can be found in the online appendix at at <ext-link ext-link-type="uri" xlink:href="http://care.diabetesjournals.org/cgi/content/full/dc09-2294">http://care.diabetesjournals.org/cgi/content/full/dc09-2294</ext-link>.</p><p>Parts of this study were presented in poster form at the 45th annual meeting of the European Association for the Study of Diabetes, Vienna, Austria, 29 September to 2 October 2009, and at the 12th annual European congress of the International Society for Pharmacoeconomics and Outcomes Research, Paris, France, 24–27 October 2009.</p></ack><ref-list><title>References</title><ref id="B1"><label>1</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hermansen</surname><given-names>K</given-names></name><name><surname>Davies</surname><given-names>M</given-names></name><name><surname>Derezinski</surname><given-names>T</given-names></name><name><surname>Martinez Ravn</surname><given-names>G</given-names></name><name><surname>Clauson</surname><given-names>P</given-names></name><name><surname>Home</surname><given-names>P</given-names></name></person-group>: <article-title>A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes</article-title>. <source>Diabetes Care</source> <year>2006</year>;<volume>29</volume>:<fpage>1269</fpage>–<lpage>1274</lpage>
<pub-id pub-id-type="pmid">16732007</pub-id></mixed-citation></ref><ref id="B2"><label>2</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Riddle</surname><given-names>MC</given-names></name><name><surname>Rosenstock</surname><given-names>J</given-names></name><name><surname>Gerich</surname><given-names>J</given-names></name></person-group>: <article-title>The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients</article-title>. <source>Diabetes Care</source> <year>2003</year>;<volume>26</volume>:<fpage>3080</fpage>–<lpage>3086</lpage>
<pub-id pub-id-type="pmid">14578243</pub-id></mixed-citation></ref><ref id="B3"><label>3</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rosenstock</surname><given-names>J</given-names></name><name><surname>Davies</surname><given-names>M</given-names></name><name><surname>Home</surname><given-names>PD</given-names></name><name><surname>Larsen</surname><given-names>J</given-names></name><name><surname>Koenen</surname><given-names>C</given-names></name><name><surname>Schernthaner</surname><given-names>G</given-names></name></person-group>: <article-title>A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes</article-title>. <source>Diabetologia</source> <year>2008</year>;<volume>51</volume>:<fpage>408</fpage>–<lpage>416</lpage>
<pub-id pub-id-type="pmid">18204830</pub-id></mixed-citation></ref><ref id="B4"><label>4</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Swinnen</surname><given-names>SG</given-names></name><name><surname>Snoek</surname><given-names>FJ</given-names></name><name><surname>Dain</surname><given-names>MP</given-names></name><name><surname>DeVries</surname><given-names>JH</given-names></name><name><surname>Hoekstra</surname><given-names>JB</given-names></name><name><surname>Holleman</surname><given-names>F</given-names></name></person-group>: <article-title>Rationale, design, and baseline data of the insulin glargine (Lantus) versus insulin detemir (Levemir) Treat-To-Target (L2T3) study: a multinational, randomized noninferiority trial of basal insulin initiation in type 2 diabetes</article-title>. <source>Diabetes Technol Ther</source> <year>2009</year>;<volume>11</volume>:<fpage>739</fpage>–<lpage>743</lpage>
<pub-id pub-id-type="pmid">19905891</pub-id></mixed-citation></ref><ref id="B5"><label>5</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bonsignore</surname><given-names>M</given-names></name><name><surname>Barkow</surname><given-names>K</given-names></name><name><surname>Jessen</surname><given-names>F</given-names></name><name><surname>Heun</surname><given-names>R</given-names></name></person-group>: <article-title>Validity of the five-item WHO Well-Being Index (WHO-5) in an elderly population</article-title>. <source>Eur Arch Psychiatry Clin Neurosci</source> <year>2001</year>;<volume>251</volume>(<issue>Suppl. 2</issue>):<fpage>II27</fpage>–<lpage>II31</lpage>
<pub-id pub-id-type="pmid">11824831</pub-id></mixed-citation></ref><ref id="B6"><label>6</label><mixed-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Bradley</surname><given-names>C</given-names></name></person-group>: <article-title>Diabetes Treatment Satisfaction Questionnaire (DTSQ)</article-title>. In <source>Handbook of Psychology and Diabetes</source>. <publisher-loc>Chur, Switzerland</publisher-loc>, <publisher-name>Harwood Academic Publishers</publisher-name> <year>1994</year>, p. <fpage>111</fpage>–<lpage>132</lpage>
</mixed-citation></ref><ref id="B7"><label>7</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cox</surname><given-names>DJ</given-names></name><name><surname>Irvine</surname><given-names>A</given-names></name><name><surname>Gonder-Frederick</surname><given-names>L</given-names></name><name><surname>Nowacek</surname><given-names>G</given-names></name><name><surname>Butterfield</surname><given-names>J</given-names></name></person-group>: <article-title>Fear of hypoglycemia: quantification, validation, and utilization</article-title>. <source>Diabetes Care</source> <year>1987</year>;<volume>10</volume>:<fpage>617</fpage>–<lpage>621</lpage>
<pub-id pub-id-type="pmid">3677982</pub-id></mixed-citation></ref><ref id="B8"><label>8</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Grootenhuis</surname><given-names>PA</given-names></name><name><surname>Snoek</surname><given-names>FJ</given-names></name><name><surname>Heine</surname><given-names>RJ</given-names></name><name><surname>Bouter</surname><given-names>LM</given-names></name></person-group>: <article-title>Development of a type 2 diabetes symptom checklist: a measure of symptom severity</article-title>. <source>Diabet Med</source> <year>1994</year>;<volume>11</volume>:<fpage>253</fpage>–<lpage>261</lpage>
<pub-id pub-id-type="pmid">8033523</pub-id></mixed-citation></ref><ref id="B9"><label>9</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Koenen</surname><given-names>C</given-names></name></person-group>: <article-title>How do detemir and glargine compare when added to oral agents in insulin-naive patients with type 2 diabetes mellitus?</article-title> <source>Nat Clin Pract Endocrinol Met</source> <year>2008</year>;<volume>4</volume>:<fpage>E1</fpage>
</mixed-citation></ref><ref id="B10"><label>10</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hollander</surname><given-names>P</given-names></name><name><surname>Cooper</surname><given-names>J</given-names></name><name><surname>Bregnhøj</surname><given-names>J</given-names></name><name><surname>Pedersen</surname><given-names>CB</given-names></name></person-group>: <article-title>A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes</article-title>. <source>Clin Ther</source> <year>2008</year>;<volume>30</volume>:<fpage>1976</fpage>–<lpage>1987</lpage>
<pub-id pub-id-type="pmid">19108786</pub-id></mixed-citation></ref><ref id="B11"><label>11</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Philis-Tsimikas</surname><given-names>A</given-names></name><name><surname>Charpentier</surname><given-names>G</given-names></name><name><surname>Clauson</surname><given-names>P</given-names></name><name><surname>Ravn</surname><given-names>GM</given-names></name><name><surname>Roberts</surname><given-names>VL</given-names></name><name><surname>Thorsteinsson</surname><given-names>B</given-names></name></person-group>: <article-title>Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes</article-title>. <source>Clin Ther</source> <year>2006</year>;<volume>28</volume>:<fpage>1569</fpage>–<lpage>1581</lpage>
<pub-id pub-id-type="pmid">17157113</pub-id></mixed-citation></ref><ref id="B12"><label>12</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Swinnen</surname><given-names>SG</given-names></name><name><surname>DeVries</surname><given-names>JH</given-names></name></person-group>: <article-title>Higher dose requirements with insulin detemir in type 2 diabetes—three cases and a review of the literature</article-title>. <source>Diabetes Res Clin Pract</source> <year>2009</year>;<volume>84</volume>:<fpage>e24</fpage>–<lpage>e26</lpage>
<pub-id pub-id-type="pmid">19251336</pub-id></mixed-citation></ref><ref id="B13"><label>13</label><mixed-citation publication-type="webpage">
<collab>European Medicines Agency</collab> <article-title>Levemir European Public Assessment Report</article-title>. <comment>Available from <ext-link ext-link-type="uri" xlink:href="http://www.emea.europa.eu/humandocs/Humans/EPAR/levemir/levemir.htm">http://www.emea.europa.eu/humandocs/Humans/EPAR/levemir/levemir.htm</ext-link></comment> <date-in-citation>Accessed 13 February 2009</date-in-citation>
</mixed-citation></ref></ref-list></back></article>